http://rdf.ncbi.nlm.nih.gov/pubchem/patent/UA-77999-C2

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-175
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2292
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-175
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
filingDate 2002-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2007-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber UA-77999-C2
titleOfInvention Thymosin-alpha 1 for treatment of malignant glioblastoma
abstract Thymosin- 1 is used as an adjuvant in combination with carmustine (BCNU) as an effective treatment for malignant glioblastoma.
priorityDate 2001-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422600775
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16130571
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555565
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2578

Total number of triples: 25.